What is the fundamental difference between Selank and Semax?

Selank is a tuftsin-derived heptapeptide studied primarily for anxiolytic and immunomodulatory effects — it works through GABAergic modulation, enkephalinase inhibition, and pro-inflammatory cytokine reduction [PMID: 21833148, PMID: 32621722]. Semax is an ACTH(4-10) fragment studied for cognitive enhancement — it works through BDNF upregulation, TrkB receptor activation, and neurotransmitter modulation [PMID: 16996037, PMID: 25313017]. In short: Selank addresses the stress and inflammation that impair cognition; Semax targets the neuroplastic machinery that underlies learning and memory.

Is there direct evidence that Selank and Semax work better together?

The most relevant evidence is a 2020 resting-state fMRI study in 52 healthy volunteers that directly compared both peptides [PMID: 32342318]. It found that Selank and Semax produced distinct yet overlapping effects on brain connectivity — Selank primarily affected amygdala-temporal cortex networks (emotional processing), while Semax affected cognitive-processing regions more prominently. However, this study characterized individual effects rather than testing the combination as a single intervention. No controlled human trial has tested Selank + Semax together as a defined protocol.

How does Selank reduce anxiety without the side effects of benzodiazepines?

Selank interacts with the GABAergic system but through mechanisms that differ from classical benzodiazepines. A clinical study in 62 patients with generalized anxiety disorder found that Selank produced anxiolytic effects comparable to medazepam but additionally showed antiasthenic and psychostimulant properties — effects opposite to the sedation typical of benzodiazepines [PMID: 18454096]. Selank also inhibits enkephalinase, enhancing endogenous opioid peptide activity rather than directly binding GABA-A receptor sites the way benzodiazepines do.

What does BDNF do, and why is it important for cognitive research?

BDNF (brain-derived neurotrophic factor) is a protein that promotes the survival, growth, and differentiation of neurons. It is particularly concentrated in the hippocampus — the brain region most critical for learning and memory. Research has shown that Semax can increase hippocampal BDNF protein levels by up to 1.4-fold and TrkB receptor phosphorylation by 1.6-fold within 3 hours of intranasal administration in animal models [PMID: 16996037]. Reduced BDNF levels have been associated with cognitive decline, depression, and neurodegenerative conditions.

Can Selank’s anti-inflammatory effects support cognitive function?

Research suggests a mechanistic link. Chronic elevation of pro-inflammatory cytokines — particularly IL-6 and TNF-alpha — is associated with impaired hippocampal function and suppressed BDNF expression. A 2020 study demonstrated that Selank can reduce IL-1-beta, IL-6, TNF-alpha, and TGF-beta1 concentrations, practically restoring them to control values [PMID: 32621722]. By reducing neuroinflammatory burden, Selank may theoretically create more favorable conditions for the neuroplastic processes that Semax is studied for enhancing.

What evidence exists from human studies versus animal models?

Both compounds have more human clinical data than most research peptides, primarily from Russian clinical programs. Selank has been studied in controlled clinical trials for generalized anxiety disorder [PMID: 18454096]. Semax has been studied in healthy volunteers using fMRI [PMID: 30225715]. The 2020 comparative fMRI study [PMID: 32342318] included 52 healthy human volunteers. However, much of the mechanistic evidence comes from animal models and cell culture studies.

Are Selank and Semax approved for human therapeutic use?

In Russia, both compounds are approved for clinical use — Selank for anxiety-related conditions and Semax for cognitive impairment and optic nerve atrophy. Outside Russia, both are classified as research-only compounds. They are not approved by the FDA, EMA, or MHRA for any therapeutic indication.

What administration routes have been studied?

Both compounds are primarily studied via **intranasal delivery**, which provides direct access to the central nervous system through the olfactory and trigeminal nerve pathways. Subcutaneous injection has also been used in some studies. Both peptides have short half-lives (measured in minutes), which is why consistent daily administration is typical in research protocols.

Research Guide

Cognitive Peptides Guide

Comprehensive research guide to cognitive peptides Selank and Semax. Mechanisms of action, BDNF modulation, anxiolytic effects, and neuroimaging evidence with PubMed citations.

Last updated Jun 11, 2026 7 min read

Most people researching cognitive peptides make one assumption immediately: Selank and Semax must be rivals — two nootropics competing for the same shelf. The research says otherwise. One calms the brain's alarm systems; the other cranks up its learning machinery. They barely overlap — which is precisely why scientists study them together.

Both emerged from Russian neuroscience programs in the 1980s and 1990s, both derive from endogenous precursors, and both reach the brain via intranasal delivery. There the resemblance ends. ** Selank **, a tuftsin analog, draws research attention for anxiolytic and immunomodulatory properties, working at the junction of stress response and cognitive function . ** Semax **, an ACTH(4-10) fragment, targets brain-derived neurotrophic factor (BDNF) and neuroplasticity, engaging the molecular machinery of learning and memory through TrkB receptor activation .

The plot thickened in 2020, when a functional connectivity study compared both peptides directly in 52 healthy volunteers using resting-state fMRI — the first neuroimaging evidence that they imprint distinct, potentially complementary signatures on emotion- and cognition-related brain networks .

Everything here reflects published clinical and preclinical literature, presented educationally — not guidance for human use, treatment, or diagnosis. Read the mechanisms first, though, and the 2020 findings stop looking surprising: two compounds touching different levers of the same machine were always going to leave different fingerprints.

Overview

Cognition is not one dial but a control room — attention, working memory, emotional regulation, executive control, long-term memory consolidation — each system running its own circuits, neurotransmitter balances, and molecular pathways. That complexity is why peptide research split along the control room's fault lines into two strategies.

Strategy one targets neurotrophic signaling: feeding the brain's own growth-and-repair machinery, led by BDNF — the molecule behind synaptic plasticity, neuronal survival, and new connection formation. Strategy two targets the stress-cognition interface: the inflammatory and hormonal responses that, chronically activated, quietly degrade performance.

Selank and Semax embody the split. Selank works the stress axis — GABAergic modulation and enkephalinase inhibition may lift the cognitive burden of chronic anxiety and neuroinflammation . Semax works the trophic axis — BDNF upregulation and TrkB activation may strengthen the synaptic plasticity underlying learning itself .

Here is where it interlocks: chronic stress and elevated pro-inflammatory cytokines (particularly IL-6 and TNF-alpha) are well-established suppressors of hippocampal BDNF expression. In other words, **neuroinflammation sabotages the exact machinery Semax tries to amplify** — which is why, in theory, calming the noise while boosting the signal could achieve what neither approach manages alone. The Cognitive Stack explores that logic; first, each compound in detail.

Compounds in This Guide

Selank

Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response

Full profile â†’

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) descends from tuftsin, an endogenous immunomodulatory peptide originally isolated from immunoglobulin G. At 751.9 Da with a short plasma half-life, it goes intranasally — improving direct CNS access while avoiding first-pass metabolism. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences engineered it as a stabilized tuftsin analog that kept the immunomodulatory résumé and added anxiolytic activity; Russia has approved it for anxiety-related conditions after multiple clinical trials.

Three mechanisms carry the research file. First, Selank inhibits enkephalinase — the enzyme degrading endogenous opioid peptides such as leu-enkephalin — potentially amplifying the body's natural calming chemistry . Clinical backing came from a trial in 62 patients with generalized anxiety disorder: Selank matched the benzodiazepine medazepam for anxiolysis while adding antiasthenic and psychostimulant properties medazepam lacked . Calm without sedation is a pharmacological unicorn.

Second, cytokine control. A 2020 study found Selank reduced IL-1-beta, IL-6, TNF-alpha, and TGF-beta1 — under inflammatory conditions, practically restoring the markers to control values . That matters for cognition because chronically elevated IL-6 and TNF-alpha associate with impaired hippocampal function and suppressed BDNF expression: quieting inflammation may protect the very substrate learning depends on.

Third, the GABAergic connection: Selank interacts with GABA-A receptors, though its binding dynamics differ from classical benzodiazepines — and studies report none of the sedation, dependence, or cognitive impairment typical of long-term benzo use . Different lockpick, different collateral damage.

The 2020 fMRI study put imaging beneath all of it: intranasal Selank shifted amygdala–temporal cortex connectivity — circuitry central to emotional processing and fear regulation . A neuroimaging fingerprint matching the behavioral file is what convergent evidence looks like — and it sets up a clean contrast with the next compound.

anxiety-reduction immune-modulation cognitive-enhancement

Semax

ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance

Full profile â†’

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is ACTH trimmed to its ACTH(4-10) core and extended with a C-terminal Pro-Gly-Pro tail for enzymatic staying power — 813.9 Da, delivered intranasally like its counterpart. Developed during the 1980s at Moscow's V.V. Zakusov Research Institute of Pharmacology, it holds Russian approval for cognitive impairment, optic nerve atrophy, and post-stroke neuroprotection. Notably absent from its file: cortisol effects — unlike its parent hormone, whatever Semax does is not stress signaling.

Its centerpiece mechanism is BDNF upregulation. The seminal 2006 study showed intranasal Semax lifted hippocampal BDNF protein up to 1.4-fold and TrkB receptor phosphorylation 1.6-fold within three hours — in the hippocampus, the region where learning lives. Earlier work had already shown dose-dependent BDNF stimulation across cortex and hippocampus .

TrkB is where BDNF cashes out: activating it triggers MAPK/ERK, PI3K/Akt, and PLC-gamma cascades that strengthen synapses, grow dendrites, and keep neurons alive. By lifting both ligand availability and receptor phosphorylation, research suggests Semax amplifies the brain's endogenous plasticity signaling rather than injecting a foreign one .

A third dimension broadens the profile: serotonergic and dopaminergic modulation, systems central to attention, motivation, and executive function . That breadth explains why studies chased mood-support and attention endpoints alongside memory and learning.

Human imaging backs the cognitive skew. A 2018 pilot saw resting-state fMRI signal rise in the default mode network after 1.2 mg intranasal Semax versus placebo in 24 healthy subjects . In the 2020 comparison, Semax's connectivity changes concentrated in regions associated with cognitive processing — the mirror image of Selank 's emotional circuitry . Two fingerprints, one experiment — exactly what the combination rationale needed.

cognitive-enhancement neuroprotection mood-support

How They Work Together

The combination case rests on a clean premise: two compounds with apparently non-overlapping targets working complementary sides of cognition.

Selank manages the noise floor — inhibiting enkephalinase to enhance endogenous opioid activity , cutting IL-6, TNF-alpha, and IL-1-beta , easing anxiety through GABAergic modulation . That is the stress-cognition interface: the well-documented pathway where chronic tension and neuroinflammation tax mental performance.

Semax amplifies the signal — BDNF protein and TrkB phosphorylation in the hippocampus , serotonergic and dopaminergic tone , heightened default mode network activity in volunteers . That is the neuroplastic infrastructure of learning and memory itself.

The lock is biochemical: stress and inflammatory cytokines suppress hippocampal BDNF, so Selank 's calm may clear the runway Semax needs. In research shorthand: one lowers the noise, the other raises the signal — a pairing whose combination should exceed either part alone, at least in theory.

The 2020 fMRI study supplied the first shared experimental frame: across 52 healthy participants, both compounds produced distinct yet overlapping connectivity effects — Selank centered on amygdala-temporal networks, Semax prominent in cognitive-processing regions — with both shared and compound-specific signatures identified .

Equally clear: no clinical trial has tested this combination in humans as a defined intervention. The synergy argument is assembled from independent studies plus one comparative scan, and deserves exploratory status. What researchers can plan practically today is the subject of the protocol notes ahead.

Frequently Asked Questions

: Selank is a tuftsin-derived heptapeptide studied primarily for anxiolytic and immunomodulatory effects — it works through GABAergic modulation, enkephalinase inhibition, and pro-inflammatory cytokine reduction [PMID: 21833148, PMID: 32621722]. Semax is an ACTH(4-10) fragment studied for cognitive enhancement — it works through BDNF upregulation, TrkB receptor activation, and neurotransmitter modulation [PMID: 16996037, PMID: 25313017]. In short: Selank addresses the stress and inflammation that impair cognition; Semax targets the neuroplastic machinery that underlies learning and memory.
: The most relevant evidence is a 2020 resting-state fMRI study in 52 healthy volunteers that directly compared both peptides [PMID: 32342318]. It found that Selank and Semax produced distinct yet overlapping effects on brain connectivity — Selank primarily affected amygdala-temporal cortex networks (emotional processing), while Semax affected cognitive-processing regions more prominently. However, this study characterized individual effects rather than testing the combination as a single intervention. No controlled human trial has tested Selank + Semax together as a defined protocol.
: Selank interacts with the GABAergic system but through mechanisms that differ from classical benzodiazepines. A clinical study in 62 patients with generalized anxiety disorder found that Selank produced anxiolytic effects comparable to medazepam but additionally showed antiasthenic and psychostimulant properties — effects opposite to the sedation typical of benzodiazepines [PMID: 18454096]. Selank also inhibits enkephalinase, enhancing endogenous opioid peptide activity rather than directly binding GABA-A receptor sites the way benzodiazepines do.
: BDNF (brain-derived neurotrophic factor) is a protein that promotes the survival, growth, and differentiation of neurons. It is particularly concentrated in the hippocampus — the brain region most critical for learning and memory. Research has shown that Semax can increase hippocampal BDNF protein levels by up to 1.4-fold and TrkB receptor phosphorylation by 1.6-fold within 3 hours of intranasal administration in animal models [PMID: 16996037]. Reduced BDNF levels have been associated with cognitive decline, depression, and neurodegenerative conditions.
: Research suggests a mechanistic link. Chronic elevation of pro-inflammatory cytokines — particularly IL-6 and TNF-alpha — is associated with impaired hippocampal function and suppressed BDNF expression. A 2020 study demonstrated that Selank can reduce IL-1-beta, IL-6, TNF-alpha, and TGF-beta1 concentrations, practically restoring them to control values [PMID: 32621722]. By reducing neuroinflammatory burden, Selank may theoretically create more favorable conditions for the neuroplastic processes that Semax is studied for enhancing.
: Both compounds have more human clinical data than most research peptides, primarily from Russian clinical programs. Selank has been studied in controlled clinical trials for generalized anxiety disorder [PMID: 18454096]. Semax has been studied in healthy volunteers using fMRI [PMID: 30225715]. The 2020 comparative fMRI study [PMID: 32342318] included 52 healthy human volunteers. However, much of the mechanistic evidence comes from animal models and cell culture studies.
: In Russia, both compounds are approved for clinical use — Selank for anxiety-related conditions and Semax for cognitive impairment and optic nerve atrophy. Outside Russia, both are classified as research-only compounds. They are not approved by the FDA, EMA, or MHRA for any therapeutic indication.
: Both compounds are primarily studied via intranasal delivery, which provides direct access to the central nervous system through the olfactory and trigeminal nerve pathways. Subcutaneous injection has also been used in some studies. Both peptides have short half-lives (measured in minutes), which is why consistent daily administration is typical in research protocols.

Summary

Selank and Semax turn out to be answers to different questions: one quiets the stress and inflammation that erode cognition — anxiolytic effects without benzodiazepine sedation — while the other reinforces the BDNF/TrkB machinery cognition runs on. Both carry clinical files from Russian neuroscience programs, both work through distinct mechanisms, and both left identifiable neural signatures in the same 52-person fMRI study.

What the literature demonstrates: two biologically active compounds with documented human and preclinical effects. What it has not shown: whether combining them produces cognitive benefits beyond what either achieves alone — a question awaiting controlled human trials.

The combination logic continues in the Cognitive Stack guide; individual profiles live at [ Selank ](/en/compounds/selank/) and [ Semax ](/en/compounds/semax/); primary studies sit on PubMed. Whichever you open next, you now know which lever each compound actually pulls.

Compounds in This Guide

Selank

Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response

Semax

ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance

I. Overview

II. Compounds in This Guide

Selank

Semax

III. How They Work Together

IV. Frequently Asked Questions

Frequently Asked Questions

V. Summary

Compounds in This Guide

Overview

Compounds in This Guide

How They Work Together

Frequently Asked Questions

Summary